Outcomes for Efavirenz versus Nevirapine-Containing Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Pillay, Prinitha ^a,b,c   Ford, Nathan ^b,d   Shubber, Zara ^e   Ferrand, Rashida A ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; TUBERCULOSTATIC AGENT; VIRUS RNA;

ARTICLE; COCHRANE LIBRARY; COHORT ANALYSIS; CONFERENCE PAPER; DEMOGRAPHY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMBASE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEDLINE; META ANALYSIS; METHODOLOGY; MORTALITY; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 84880726653     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068995     Document Type: Article

References (55)

1. World Health Organisation (2010) Antiretroviral therapy for HIV infection in adults and adolescents. Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed May 2013.
2. US Department of Health and Human Services. What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient {pipe} Adult and Adolescent ARV Guidelines {pipe} AIDSinfo. Available from: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/11/what-to-start. Accessed May 2013.
3. Thompson MA, Aberg JA, Cahn P, (2010) Antiretroviral Treatment of Adult HIV Infection: 2010 Recommendations of the International AIDS Society-USA Panel. JAMA: The Journal of the American Medical Association. 304(3): 321-33.
4. World Health Organisation (2012) WHO {pipe} Use of efavirenz during pregnancy: A public health perspective. Available from: http://www.who.int/hiv/pub/treatment2/efavirenz/en/index.html. Accessed May 2013.
5. Mbuagbaw LCE, Irlam JH (2009) Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection. Cochrane Database of Systematic Reviews. dx.doi.org/10.1002/14651858.CD004246.pub2.
6. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, et al. (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. The Lancet. 363(9417): 1253-63.
7. Tang MW, Kanki PJ, Shafer RW, (2012) A Review of the Virological Efficacy of the 4 World Health Organization-Recommended Tenofovir-Containing Regimens for Initial HIV Therapy. Clinical Infectious Diseases. 54(6): 862-75.
8. The Cochrane Collaboration; Review Manager (RevMan) Version. 5 (0): 2008.
9. GRADE working group. Available from: http://www.gradeworkinggroup.org/Accessed May 2013.
10. Higgins JP GS (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from: http://www.cochrane-handbook.org/Accessed May 2013.
11. Wit F, Phanuphak P, Ruxrungtham K, Baraldi E, Malan N, et al. (2007) Three-year extended follow-up of the 2NN study: a randomised comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine, efavirenz or both drugs combined, together with stavudine and lamivudine. Poster exhibition: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Abstract no. WEPEB032.
12. van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal M, Novak R, et al. (2008) Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-Term Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Initial Therapy in HIV-1-Infected Persons. HIV clinical trials. 9(5): 324-36.
13. Villar J, Sánchez P, González A, Sorli L, Montero MM, et al. (2011) Use of Non-Nucleoside Analogues Together with Rifampin in HIV Patients with Tuberculosis. HIV clinical trials. 12(3): 171-4.
14. Núñez M, Soriano V, Martín-Carbonero L, Barrios A, Barreiro P, et al. (2002) SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV clinical trials. 3(3): 186-94.
15. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, et al. (2011) Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 53(7): 716-24.
16. Pérez-Elías MJ, Moreno A, Moreno S, López D, Antela A, et al. (2005) Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. HIV clinical trials. 6(6): 312-9.
17. Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, et al. (2012) Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes. 60(4): 428-37.
18. Important Change in SUSTIVA® (efavirenz) Package Insert - Change from Pregnancy Category C to D. 2005.
19. HIV-Causal Collaboration, (2012) The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS. 26(13): 1691-705.
20. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, et al. (2009) A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse-Transcriptase Inhibitor-Based Regimens in HIV-Infected Patients Receiving Rifampicin: The N2R Study. Clinical Infectious Diseases. 48(12): 1752-9.
21. Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, et al. (2013) Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. The Lancet infectious diseases. 13(4): 303-12.
22. Matteelli A, Carvalho AC, Kouanda S, Saleri N, Ouedraogo G, et al. (2013) Efficacy and Safety of Nevirapine- vs Efavirenz based ART in TB/HIV patients in Burkina Faso: A Clinical and Pharmacokinetic Study. 20th Conference on Retroviruses and Opportunistic Infections: Abstract47462.
23. Shipton LK, Wester CW, Stock S, Ndwapi N, Gaolathe T, et al. (2009) Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis. 13(3): 360-6.
24. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S (2008) Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV medicine. 294-9.
25. Amoroso A, Etienne-Mesubi M, Edozien A, Ojoo S, Sheneberger R, et al. (2012) Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. J Acquir Immune Defic Syndr. 60(3): 314-20.
26. Bock P, Fatti G, Grimwood A (2010) Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral treatment amongst an adult treatment cohort from South Africa. Journal of the International AIDS Society. (Suppl 4): 10.
27. Wester CW, Thomas AM, Bussmann H, Moyo S, Makhema JM, et al. (2010) Non-Nucleoside Reverse Transcriptase Inhibitor Outcomes Among cART-Treated Adults in Botswana. AIDS. (Suppl 1): S27-S36.
28. Cozzi-Lepri A, Phillips AN, D'Arminio Monforte A, Piersantelli N, Orani A, et al. (2002) Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. Journal of Infectious Diseases. 1062-9.
29. Chung U, Fichtenbaum CJ (2002) A minority of patients achieve long-term durable viral suppression with potent antiretroviral therapy. Poster Exhibition: The XIV International AIDS Conference: Abstract no. TuPeB4452.
30. Castillo-Mancilla JR, Campbell TB, (2012) Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settings. Journal of comparative effectiveness research. 1(2): 157-70.
31. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, et al. (2013) Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 27(9): 1403-12.
32. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM, (2009) Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. Feb 15(48(4)): 484-8.
33. Braithwaite RS, Kozal MJ, Chang CCH, Roberts MS, Fultz SL, et al. (2007) Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 21(12): 1579-89.
34. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, et al. (2008) Efavirenz versus Nevirapine-based Initial Treatment of HIV Infection: Clinical and Virological Outcomes in Southern African Adults. AIDS (London, England). 22(16): 2117-25.
35. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Annals of Internal Medicine. 564-73.
36. Ford N, Calmy A, Mofenson L, (2011) Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 25(18): 2301-4.
37. Campaign for access to essential medicines. Médecins Sans Frontières. Untangling the Web of Antiretroviral Price Reductions. Available from: http://utw.msfaccess.org/. Accessed May 2013.
38. Gaytan JJA, De La Garza ERZ, GarciaMC, Chavez SBV (2004) Nevirapine or efavirenz in combination with two nucleoside analogues in HIV-infected antiretroviral-naive patients. Medicina Interna de Mexico 20(1): 24-33. [: CN-00641209].
39. Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, et al. (2011) Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the DAYANA Trial, IMEA032/ANRS12115. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Abstract noCDB277.
40. Keiser P, Nassar N, White C, Koen G, Moreno S, (2002) Comparison of Nevirapine- and Efavirenz-Containing Antiretroviral Regimens in Antiretroviral-Naïve Patients: A Cohort Study. HIV clinical trials. 3(4): 296-303.
41. Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, et al. (2009) The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. Journal of Acquired Immune Deficiency Syndromes. 140-6.
42. Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, et al. (2011) A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV medicine. 12(5): 259-68.
43. Hamers RL, Schuurman R, Sigaloff KCE, Wallis CL, Kityo C, et al. (2012) Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: A multicentre cohort study. The Lancet infectious diseases. 307-17.
44. Cortes C, Beltran C, Wolff M, (2010) Comparison of efavirenz and nevirapine based HAART regimens in 4187 patients with up to 6 years of follow up, a prospective, open label observational study. 14th International Congress on Infectious Diseases (ICID) Abstracts. 2010: e242 doi: 10.1016/j.ijid.2010.02.2026.
45. Castelnuovo B, Sempa J, Agnes KN, Kamya MR, Manabe YC (2011) Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited Settings. AIDS Research and Treatment, vol. 2011, Article ID 736938. doi: 10.1155/2011/736938.
46. Antiretroviral Therapy Cohort Collaboration (ART CC) (2006) Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. The Journal of infectious diseases. 194(5): 612-22.
47. Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, et al. (2008) Does short-term virologic failure translate to clinical events in antiretroviral-naive patients initiating antiretroviral therapy in clinical practice? The Antiretroviral Therapy Cohort Collaboration (ART-CC). AIDS. 2481-92.
48. Hartmann M, Witte S, Brust J, Schuster D, Mosthaf F, et al. (2005) Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort). International journal of STD & AIDS. 16(6): 404-9.
49. Manfredi RMD, Calza LMD, Chiodo FMD, (2004) Efavirenz Versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label Observational Study. J Acquir Immune Defic Syndr. 35(5): 492-502.
50. De Beaudrap P, Etard JF, Gueye FN, Gueye M, Landman R, et al. (2008) Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. AIDS research and human retroviruses. 753-60.
51. Wallis CL, Papathanasopolous MA, Fox M, Conradie F, Ive P, et al. (2012) Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antiviral therapy. 313-20.
52. Darin K, Scarsi K, Meloni S, Rawizza H, Chang C, et al. (2010) Clinical and virologic outcomes of six first-line regimens in a large ART program in Nigeria. XVIII International AIDS Conference: Abstract no THPE01172010.
53. von Giesen HJ, Köller H, de Nocker D, Haslinger BA, Arendt G, (2003) Long-term safety and efficacy of NNRTI within the central nervous system. HIV clinical trials. 4(6): 382-90.
54. Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, et al. (2011) Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort. HIV medicine. 352-60.
55. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A, (2004) Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection. HIV medicine. 5(2): 105-9.